Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 7/20 | 0.49 |
| ▸ | LGALS7; LGALS7B | P47929 | 2/20 | 0.48 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.48 |
| ▸ | BDNF | P23560 | 3/20 | 0.47 |
| ▸ | MDK | P21741 | 3/20 | 0.47 |
| ▸ | PTN | P21246 | 2/20 | 0.47 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.47 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.47 |
| ▸ | LGALS9 | O00182 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | CD69 | Q07108 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dermatan SCHEMBL16311126 | 1.00 | LGALS3 (0.49) | LGALS3LGALS7; LGALS7BLGALS1BDNFMDK | |
| Dermatan SCHEMBL29360360 | 1.00 | LGALS3 (0.49) | LGALS3LGALS7; LGALS7BLGALS1BDNFMDK | |
| Dermatan SCHEMBL13472480 | 1.00 | LGALS3 (0.49) | LGALS3LGALS7; LGALS7BLGALS1BDNFMDK | |
| Dermatan SCHEMBL18232151 | 1.00 | LGALS3 (0.49) | LGALS3LGALS7; LGALS7BLGALS1BDNFMDK | |
| Dermatan SCHEMBL19846466 | 1.00 | LGALS3 (0.49) | LGALS3LGALS7; LGALS7BLGALS1BDNFMDK | |
| Dermatan SCHEMBL19184706 | 1.00 | LGALS3 (0.49) | LGALS3LGALS7; LGALS7BLGALS1BDNFMDK | |
| SCHEMBL24844372 | 0.98 | BDNF (0.50) | LGALS3LGALS7; LGALS7BLGALS1BDNFMDK | |
| SCHEMBL14497205 | 0.98 | BDNF (0.50) | LGALS3LGALS7; LGALS7BLGALS1BDNFMDK | |
| SCHEMBL25785578 | 0.98 | BDNF (0.50) | LGALS3LGALS7; LGALS7BLGALS1BDNFMDK | |
| SCHEMBL19295777 | 0.96 | BDNF (0.49) | LGALS3LGALS7; LGALS7BLGALS1BDNFMDK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240026404-A1 | CELLULAR GLYCOSAMINOGLYCAN COMPOSITIONS AND METHODS OF MAKING AND USING | TEGA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11707473-B2 | Method for the manufacture and use of a bionic hydrogel composition for medical applications | Qventis GmbH (DE) | 2023-07-25 | — | — | US | disclosed |
| US-20180168316-A1 | Packaged Skin Treatment Composition And Method | ELC MANAGEMENT LLC | 2018-06-21 | — | — | US | disclosed |
| US-9492586-B2 | Derivatives of hyaluronic acid capable of forming hydrogels | CONTIPRO BIOTECH S.R.O. (CZ) | 2016-11-15 | — | — | US | disclosed |
| US-9433644-B2 | Formulations and methods for treating oral inflammation, injury, or pain | RUTGILLI PHARMACEUTICALS, LLC (US) | 2016-09-06 | — | — | US | disclosed |
| US-20150119783-A1 | Method of Preparation of Polysaccharide Fibres, Wound Covers that Contain Them, Method of Manufacturing of Wound Covers, and Apparatus for Preparation of Polysaccharide Fibres | CONTIPRO BIOTECH S.R.O. (CZ) | 2015-04-30 | — | — | US | disclosed |
| US-20150030694-A1 | FORMULATIONS AND METHODS FOR TREATING ORAL INFLAMMATION, INJURY, OR PAIN | INVADO LABORATORIES, LLC | 2015-01-29 | — | — | US | disclosed |
| US-20150000561-A1 | Derivates Based on Hyaluronic Acid, Capable of Forming Hydrogels, Method of Preparation Thereof, Hydrogels Based on Said Derivatives, Method of Preparation Thereof and Use | CONTIPRO A.S. (CZ) | 2015-01-01 | — | — | US | disclosed |
| US-20140363502-A1 | Resveratrol-Containing Compositions and Methods of Use for Treatment of Macular Degeneration | RESVERATROL PARTNERS LLC (US) | 2014-12-11 | — | — | US | disclosed |
| US-20120245518-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF BLADDER DISORDERS | RITCHER GEDEON NYRT. (HU) | 2012-09-27 | — | — | US | disclosed |
| US-20100248260-A1 | GLYCOSAMINOGLYCAN-COATED PARTICLES AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100173228-A1 | Nanotube and Carbon Layer Nanostructured Composites | UNIVERSITY OF WOLLONGONG (AU) | 2010-07-08 | — | — | US | disclosed |
| US-20100087798-A1 | SYSTEMS, METHODS AND DEVICES FOR USING A FLOWABLE MEDIUM FOR DISTENDING A HOLLOW ORGAN | INTERLACE MEDICAL, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100068461-A1 | NANOSTRUCTURED COMPOSITES | UNIVERSITY OF WOLLONGONG (AU) | 2010-03-18 | — | — | US | disclosed |
| US-20100022471-A1 | Oral Moisturizer for Alleviating Dry Mouth | SAGE PRODUCTS INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100023101-A1 | BIOCOMPATIBLE COMPOSITES | UNIVERSITY OF WOLLONGONG (AU) | 2010-01-28 | — | — | US | disclosed |
| US-20090169585-A1 | Resveratrol-Containing Compositions And Their Use In Modulating Gene Product Concentration Or Activity | RESVERATROL PARTNERS, LLC (US) | 2009-07-02 | — | — | US | disclosed |
| US-20070203094-A1 | Esters Of Hyaluronic Acid With Rhein, Process For Their Preparation And Compositions Comprising The Same | LABROATOIRE MEDIDOM S.A. (CH) | 2007-08-30 | — | — | US | disclosed |
| US-7238677-B2 | Prevention of urogenital infections | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070123488-A1 | Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100023101-A1 | BIOCOMPATIBLE COMPOSITES | F12, MATR3, FIBP | LGALS3 1222/4885LGALS7; LGALS7B 1728/4885LGALS1 1025/4885 |
| US-20070123488-A1 | Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis | CD44, SLC30A7, SLC30A6 | LGALS3 753/4885LGALS7; LGALS7B 881/4885LGALS1 987/4885 |
| US-20090169585-A1 | Resveratrol-Containing Compositions And Their Use In Modulating Gene Product Concentration Or Activity | IGFBP6, SIRT6, IP6K1 | LGALS3 1913/4885LGALS7; LGALS7B 2381/4885LGALS1 1295/4885 |
| US-20150030694-A1 | FORMULATIONS AND METHODS FOR TREATING ORAL INFLAMMATION, INJURY, OR PAIN | CD44, TRPV1, IL6 | LGALS3 344/4885LGALS7; LGALS7B 1104/4885LGALS1 528/4885 |
| US-20120245518-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF BLADDER DISORDERS | SLC30A7, SLC39A11, SLC30A6 | LGALS3 316/4885LGALS7; LGALS7B 353/4885LGALS1 424/4885 |
| US-20140363502-A1 | Resveratrol-Containing Compositions and Methods of Use for Treatment of Macular Degeneration | IGFBP6, SIRT6, STRA6 | LGALS3 1262/4885LGALS7; LGALS7B 2480/4885LGALS1 1032/4885 |
| US-20070203094-A1 | Esters Of Hyaluronic Acid With Rhein, Process For Their Preparation And Compositions Comprising The Same | CD44, RDX, RALA | LGALS3 2434/4885LGALS7; LGALS7B 1901/4885LGALS1 2238/4885 |
| US-20240026404-A1 | CELLULAR GLYCOSAMINOGLYCAN COMPOSITIONS AND METHODS OF MAKING AND USING | CD44, CSGALNACT1, HPSE | LGALS3 64/4885LGALS7; LGALS7B 169/4885LGALS1 143/4885 |
| US-20100022471-A1 | Oral Moisturizer for Alleviating Dry Mouth | TAS2R40, TAS2R60, TREH | LGALS3 2089/4885LGALS7; LGALS7B 2456/4885LGALS1 1667/4885 |
| US-11707473-B2 | Method for the manufacture and use of a bionic hydrogel composition for medical applications | HLCS, CD44, PLOD3 | LGALS3 168/4885LGALS7; LGALS7B 145/4885LGALS1 63/4885 |
| US-20180168316-A1 | Packaged Skin Treatment Composition And Method | CUTA, KRT18, EXOSC5 | LGALS3 3777/4885LGALS7; LGALS7B 3325/4885LGALS1 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.